SL
SVB Leerink Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
126
Quanterix
QTRX
$211M
|
PS
Puneet Souda
| $4.55 | $15 |
230%
upside
| Market Perform |
9 Nov ‘22
2 years ago |
|
127
Talkspace
TALK
$437M
|
SD
Stephanie Davis
| $2.61 | $1 |
62%
downside
| Market Perform |
9 Nov ‘22
2 years ago |
|
128
NeoGenomics
NEO
$1.03B
|
PS
Puneet Souda
| $7.98 | $15 |
88%
upside
| Outperform |
9 Nov ‘22
2 years ago |
|
129
Clover Health Investments
CLOV
$1.41B
|
WM
Whit Mayo
| $2.75 | $1.50 |
45%
downside
| Market Perform |
8 Nov ‘22
2 years ago |
|
130
CRISPR Therapeutics
CRSP
$4.99B
|
MF
Mani Foroohar
| $54.86 | $76 |
39%
upside
| Outperform |
7 Nov ‘22
2 years ago |
|
131
Immunovant
IMVT
$2.99B
|
MK
Mike Kratky
| $17.14 | $14 |
18%
downside
| Outperform |
4 Nov ‘22
2 years ago |
|
132
Agilon Health
AGL
$497M
|
WM
Whit Mayo
| $1.20 | $30 |
2,400%
upside
| Outperform |
4 Nov ‘22
2 years ago |
|
133
Pediatrix Medical
MD
$1.49B
|
WM
Whit Mayo
| $17.07 | $16 |
6%
downside
| Market Perform |
4 Nov ‘22
2 years ago |
|
134
Aurinia Pharmaceuticals
AUPH
$1.63B
|
JS
Joseph Schwartz
| $12.40 | $12 |
3%
downside
| Outperform |
4 Nov ‘22
2 years ago |
|
135
Merus
MRUS
$5.1B
|
AB
Andrew Berens
| $67.47 | $35 |
48%
downside
| Outperform |
4 Nov ‘22
2 years ago |
|
136
Ultragenyx Pharmaceutical
RARE
$3.07B
|
JS
Joseph Schwartz
| $31.82 | $108 |
239%
upside
| Outperform |
3 Nov ‘22
2 years ago |
|
137
Arcus Biosciences
RCUS
$1.3B
|
DG
Daina Graybosch
| $12.19 | $38 |
212%
upside
| Outperform |
3 Nov ‘22
2 years ago |
|
138
Humana
HUM
$37B
|
WM
Whit Mayo
| $307.92 | $640 |
108%
upside
| Outperform |
3 Nov ‘22
2 years ago |
|
139
Aligos Therapeutics
ALGS
$78.8M
|
RR
Roanna Ruiz
| $11.34 | $50 |
341%
upside
| Market Perform |
3 Nov ‘22
2 years ago |
|
140
Veracyte
VCYT
$2.55B
|
PS
Puneet Souda
| $32.43 | $35 |
8%
upside
| Outperform |
3 Nov ‘22
2 years ago |
|
141
Omnicell
OMCL
$1.47B
|
JZ
Joy Zhang
| $32.11 | $54 |
68%
upside
| Market Perform |
3 Nov ‘22
2 years ago |
|
142
Myriad Genetics
MYGN
$615M
|
PS
Puneet Souda
| $6.61 | $25 |
278%
upside
| Market Perform |
2 Nov ‘22
2 years ago |
|
143
Neurocrine Biosciences
NBIX
$14.3B
|
MG
Marc Goodman
| $144.10 | $115 |
20%
downside
| Market Perform |
2 Nov ‘22
2 years ago |
|
144
Merck
MRK
$212B
|
JLR
Jeffrey La Rosa
| $84.71 | $112 |
32%
upside
| Outperform |
28 Oct ‘22
2 years ago |
|
145
Insmed
INSM
$30.7B
|
JS
Joseph Schwartz
| $145.10 | $50 |
66%
downside
| Outperform |
27 Oct ‘22
2 years ago |
|
146
Universal Health Services
UHS
$12.1B
|
WM
Whit Mayo
| $190.12 | $114 |
40%
downside
| Market Perform |
27 Oct ‘22
2 years ago |
|
147
Biogen
BIIB
$20.6B
|
MG
Marc Goodman
| $140.67 | $310 |
120%
upside
| Outperform |
26 Oct ‘22
2 years ago |
|
148
Tenet Healthcare
THC
$17.3B
|
WM
Whit Mayo
| $196.18 | $55 |
72%
downside
| Outperform |
25 Oct ‘22
2 years ago |
|
149
Immunic
IMUX
$75.1M
|
TS
Thomas Smith
| $0.7610 | $5 |
557%
upside
| Market Perform |
21 Oct ‘22
2 years ago |
|
150
Tourmaline Bio
TRML
$687M
|
MF
Mani Foroohar
| $26.74 | $20 |
25%
downside
| Market Perform |
20 Oct ‘22
2 years ago |
|